Department of Cardiology, Yidu Central Hospital of Qingzhou, Weifang, Shandong, China (mainland).
Department of Intensive Care, Yidu Central Hospital of Qingzhou, Weifang, Shandong, China (mainland).
Med Sci Monit. 2018 Oct 23;24:7556-7562. doi: 10.12659/MSM.911531.
BACKGROUND PTPN3 was demonstrated to be involved in the progression of several types of cancers, such as gastric adenocarcinoma, lung cancer, and intrahepatic cholangiocarcinoma. However, its clinical significance in glioblastoma (GBM) has not been elucidated. MATERIAL AND METHODS We investigated the expression of PTPN3 in 95 cases of GBM with immunohistochemistry and in 8 pairs of fresh GBMs and their adjacent tissues with qualitative polymerase chain reaction. Moreover, the correlation between PTPN3 and clinicopathological factors was evaluated by chi-square test. The prognostic value of PTPN3 was investigated with univariate analysis and multivariate analysis. With MTT assay and Transwell assay, the oncogenic functions of PTPN3 in GBM proliferation and invasion were further investigated. RESULTS Expression of PTPN3 in GBM tissues was significantly higher than in their corresponding adjacent tissues. High expression of PTPN3 was significantly associated with unfavorable prognosis of GBM. Moreover, in GBM cell lines, PTPN3 promoted cell proliferation and invasion, and the PTP common inhibitor pervanadate suppressed GBM proliferation and invasion. CONCLUSIONS Our experiments show that PTPN3 is an independent prognostic factor in GBM and indicated that postoperative detection of PTPN3 can be used to identify high-risk patients and guide individual treatment.
PTPN3 被证明参与了多种类型癌症的进展，如胃腺癌、肺癌和肝内胆管癌。然而，其在胶质母细胞瘤（GBM）中的临床意义尚未阐明。
我们通过免疫组织化学检测了 95 例 GBM 中 PTPN3 的表达情况，并通过定性聚合酶链反应检测了 8 对新鲜 GBM 及其相邻组织中 PTPN3 的表达情况。此外，通过卡方检验评估了 PTPN3 与临床病理因素之间的相关性。通过单因素和多因素分析研究了 PTPN3 的预后价值。通过 MTT 测定和 Transwell 测定进一步研究了 PTPN3 在 GBM 增殖和侵袭中的致癌作用。
GBM 组织中 PTPN3 的表达明显高于相应的相邻组织。PTPN3 的高表达与 GBM 的不良预后显著相关。此外，在 GBM 细胞系中，PTPN3 促进了细胞的增殖和侵袭，而 PTP 共同抑制剂过钒酸盐则抑制了 GBM 的增殖和侵袭。
我们的实验表明 PTPN3 是 GBM 的一个独立预后因素，并表明术后检测 PTPN3 可用于识别高危患者并指导个体化治疗。
